Becker's Hospital Review

9 Recommendations to Reduce Multiple Infusion Risk

At a recent meeting of the AAMI Healthcare Technology Safety Institute, researchers from the University of Toronto released a report that provides nine specific recommendations to reduce the risks ...
Nasdaq

FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis

– Approval based on data from the randomized, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional Ocrevus dosing regimen – – Shorter infusion time will further improve the ...
Monthly Prescribing Reference

FDA Approves Shorter Infusion Time for MS Drug Ocrevus

The approval was based on data from the phase 3b ENSEMBLE PLUS study that compared the frequency and severity of infusion-related reactions for a 2-hour Ocrevus infusion time to the previously ...
Mena FN

New Published Study Shows Medlite ID As Faster And Simpler Solution To Primary Medication Infusion Line Identification

At Orion Innovations, we are advancing new and disruptive healthcare technologies that improve patient experience, support caregivers, and enhance the bottom line. MedLite ID identifies and ...
Business Wire

FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a ...